OncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the stock.

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $4.25 price target on shares of OncoCyte in a report on Wednesday, November 13th.

OncoCyte Stock Performance

Shares of OCX stock opened at $2.23 on Tuesday. OncoCyte has a twelve month low of $1.97 and a twelve month high of $3.57. The firm has a fifty day simple moving average of $2.50 and a 200-day simple moving average of $2.87.

OncoCyte (NASDAQ:OCX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.54). OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. The business had revenue of $0.12 million during the quarter. During the same period in the prior year, the company earned ($0.57) earnings per share. As a group, equities analysts predict that OncoCyte will post -2.57 earnings per share for the current fiscal year.

Insider Buying and Selling at OncoCyte

In other OncoCyte news, CFO Andrea S. James bought 20,000 shares of the company’s stock in a transaction that occurred on Thursday, December 5th. The shares were acquired at an average cost of $2.29 per share, for a total transaction of $45,800.00. Following the acquisition, the chief financial officer now directly owns 53,670 shares of the company’s stock, valued at $122,904.30. This trade represents a 59.40 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Patrick W. Smith purchased 90,219 shares of the firm’s stock in a transaction on Thursday, December 26th. The stock was acquired at an average price of $2.13 per share, for a total transaction of $192,166.47. Following the transaction, the insider now owns 1,773,903 shares of the company’s stock, valued at $3,778,413.39. The trade was a 5.36 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 122,719 shares of company stock valued at $264,341. 1.58% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in OncoCyte stock. Geode Capital Management LLC boosted its holdings in shares of OncoCyte Co. (NASDAQ:OCX) by 12.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 103,980 shares of the company’s stock after buying an additional 11,289 shares during the period. Geode Capital Management LLC owned approximately 0.62% of OncoCyte worth $296,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 55.35% of the company’s stock.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.